LOGIN / SKAPA KONTO
Aktuellt
Summary Palliative care should be offered together with disease-modifying therapies, to meet physical, psychosocial, social and spiritual needs. ERS SATELITTE 2026 COPD: Addressing the serious suffering in COPD: palliative care Speaker Daisy Janssen, Professor...
Addressing treatable traits important part of precision medicine in COPD Breakthroughs in COPD care are not always dramatic innovations but often consist of quieter, meaningful advances that improve patient outcomes, says prof. Nicholas Roche....
Sammendrag At this year’s ERS Satellite, Professor Surya Bhatt presented a compelling update on the evolving diagnostic paradigm in chronic obstructive pulmonary disease (COPD), grounded in the recent landmark JAMA publication proposing a multidimensional...
Sammendrag The focus of COPD management should be shifted towards primary prevention, argues Professor Gappa, as a growing body of evidence points towards childhood events predisposing individuals for COPD. ERS SATELITTE 2026 Primary prevention...
Sammendrag House dust mite-induced allergic rhinitis affects approximately 40% of the global population and significantly impacts sleep, school performance, and work productivity. ERS SATELITTE 2026 Allergen Immunotherapy for the Prevention and Treatment of Asthma...
ERS satellite, March 2026ASTHMA A Patient-centred approach to understanding the spectrum of asthma management SpeakerProfessor António Jaime Correia De SousaMohamed Shamji, United Kingdom The Evidence for Supported Self-Management in asthma is overwhelming Asthma care...
Sammendrag Occupational asthma can be caused by irritants or via sensitising, either IgE-mediated or unknown pathomechanisms. Identifying the source is key to find a feasible solution. ERS SATELITTE 2026 Asthma in the workplace Speaker...
ERS satellite, March 2026ASTHMA: Allergen Immunotherapy for the Prevention and Treatment of Asthma SpeakerMohamed Shamji, United Kingdom Disease burden and united airway concept Allergic rhinitis induced by house dust mite (HDM) affects approximately 40%...
Chiesi er et familieeid legemiddelselskap grunnlagt i 1935. Vi tror på innovasjon, ansvar og menneskelig empati. Vår lidenskap er å forbedre livskvaliteten for pasienter over hele verden gjennom forskning, utvikling og bærekraftige løsninger.
© 2026 Chiesi Pharma AB. Dette nettstedet er beregnet på helsepersonell i Norge.